Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.
A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...
Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...
Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – ...
Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.
A Phase 1 study of MNA-001, which targets TREM2, saw age-linked markers in elderly volunteers shift toward levels seen in ...
Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.
L-Nutra Health launches a clinician-led metabolic program in London, built on a patented plant-based diet designed to mimic ...
John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...
Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...
Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.
Twelve abstracts head to The Liver Meeting, including a real-world comparison with resmetirom and four on investigational efruxifermin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results